JPMorgan Kicks Off US Bank Bond Sales Ahead of Seasonal Slowdown
The lender is marketing 11-year subordinated notes that are fixed-to-floating rate and that can't be called for 10 years, according to a person familiar with the matter. Initial price discussions call for a yield around 1.4 percentage points above similarly dated Treasuries, said the person, who was not authorized to speak publicly.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Nvidia's China Nightmare? H20 Chip Faces Backdoor Allegations in High-Stakes Trade Showdown
China's been turning up the heat on Nvidia (NASDAQ:NVDA), and not in a good way. This week, the country's top internet watchdog summoned Nvidia reps over what it calls serious security risks tied to the H20 chipa product Nvidia designed specifically to meet U.S. export rules. State media pulled no punches either. In a commentary published Friday, the People's Daily warned of potential chip backdoors triggering a nightmare, saying it couldn't allow infected semiconductors into its digital infrastructure. Nvidia responded firmly: Cybersecurity is critically important to us, adding that its chips don't contain any remote access pathways. Still, in today's geopolitical climate, that reassurance may not be enough. Warning! GuruFocus has detected 5 Warning Signs with NVDA. Here's where things get messier. Just a few weeks ago, the U.S. agreed to lift restrictions on H20 sales to China as part of a broader deal involving rare-earth magnetsmaterials critical for everything from smartphones to fighter jets. Commerce Secretary Howard Lutnick had framed the H20 resumption as a meaningful breakthrough after bilateral talks in London, and Treasury Secretary Scott Bessent said the magnet issue was solved. But with Beijing now putting the H20 back under the microscope, it's unclear whether Nvidia has actually received the licenses it needs to ship the chips. And if China decides the H20 isn't up to pareither technically or politicallythose sales may stall before they even start. Meanwhile, CEO Jensen Huang has been walking a tightrope. Fresh off a high-profile visit to Beijing, Huang praised China's AI momentum and national champions like DeepSeek, all while pushing back on the idea that Nvidia would ever install surveillance backdoors into its products. He called the suggestion not only false, but bad business. Still, the reality is this: Nvidia's H20, already weaker than its flagship GPUs, now faces a political test that could matter more than its specs. Investors watching the tech standoff might want to pay close attention to what happens nextbecause this chip is turning into a geopolitical bargaining chip. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
5 minutes ago
- Yahoo
Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 43,700,000 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 5,700,000 additional shares of its common stock, at a public offering price of $3.30 per share. The underwriters did not receive any discounts or commissions with respect to an aggregate of 1,818,181 shares of common stock sold to the Cystic Fibrosis Foundation. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $144.2 million. TD Cowen and BMO Capital Markets acted as joint book-running managers for the offering. The shares of common stock were offered by Prime Medicine pursuant to an effective shelf registration statement on Form S-3 that was previously filed with the U.S. Securities and Exchange Commission (SEC) on November 3, 2023 and declared effective by the SEC on November 13, 2023 (File No. 333-275321). The offering was made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC's website at Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846, or by email at or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 151 West 42nd Street, 32nd Floor, New York, New York 10036, by email at bmoprospectus@ This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. About Prime Medicine Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Prime Editors are designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications. Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path. Investor and Media ContactsGregory DearbornPrime Medicine857-209-0696gdearborn@ Hannah DeresiewiczPrecision
Yahoo
5 minutes ago
- Yahoo
S&P 500 sinks 1.6%, its worst drop since May, following surprisingly weak hiring numbers and Trump's tariff rollout
NEW YORK (AP) — S&P 500 sinks 1.6%, its worst drop since May, following surprisingly weak hiring numbers and Trump's tariff rollout. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
